OPTUS Pharmaceutical Valuation

Q: What is the Fair Price of A131030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A131030 (₩5460) is trading below our estimate of [[fair value]] (₩36286.12)

Is A131030 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A131030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A131030 (₩5460) is trading below our estimate of fair value (₩36286.12)

Significantly Below Fair Value: A131030 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A131030?

Key metric: As A131030 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A131030. This is calculated by dividing A131030's market cap by their current earnings.
What is A131030's PE Ratio?
PE Ratio	8.6x
Earnings	₩10.25b
Market Cap	₩88.20b

A131030 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	1.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A131030's PE Ratio compare to its peers?

The above table shows the PE ratio for A131030 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	29.9x
A059210 Meta Biomed	5.6x	n/a	₩83.1b
A100700 Sewoon Medical	8x	n/a	₩113.0b
A142280 Green Cross Medical Science	69.8x	n/a	₩82.1b
A450330 HASS	36.4x	n/a	₩61.4b
A131030 OPTUS Pharmaceutical	8.6x	n/a	₩88.2b

Price-To-Earnings vs Peers: A131030 is good value based on its Price-To-Earnings Ratio (8.6x) compared to the peer average (29.9x).

Price to Earnings Ratio vs Industry

How does A131030's PE Ratio compare vs other companies in the KR Medical Equipment Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A035610 Solborn	2.6x	n/a	US$68.56m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A131030 is good value based on its Price-To-Earnings Ratio (8.6x) compared to the KR Medical Equipment industry average (13.8x).

Price to Earnings Ratio vs Fair Ratio

What is A131030's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A131030 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	8.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A131030's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Access Bio

₩189.3b

Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

A950130

₩5,600.00

0.2%

-38.9%

Wonbiogen

₩44.8b

Develops and sells medical equipment in South Korea.

A307280

₩1,262.00

1.9%

-18.7%

Boditech Med

₩356.7b

Offers instruments and diagnostic reagents in South Korea and internationally.

A206640

₩16,230.00

1.3%

-5.0%